ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1912

Meteorological Variables Have Different Effect on Core Measures of Disease Activity in Patients with Rheumatoid Arthritis
Abstract Number: 0482

Metformin Use Reduces the Risk of Developing Osteoarthritis: A Propensity Score Matching Study
Abstract Number: 1532

Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
Abstract Number: 0261

Methotrexate Withdrawal and Outcomes in Participants with Well-controlled Non-systemic JIA Within the CARRA Registry
Abstract Number: 1622

Mind the Gap: The Experience of Adolescents in a Rheumatology Transition Clinic
Abstract Number: 1244

Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid Arthritis in Clinical Remission but Elevated Negative PROs: A Pragmatic Pilot Study
Abstract Number: 1669

Minimal Erosive Volume Needed for Radiographic Identification of Erosions in the Metacarpophalangeal Joints in Rheumatoid Arthritis. a Comparative Analysis of High Resolution Peripheral Quantitative Computed Tomography and Conventional Radiography
Abstract Number: 0923

Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study
Abstract Number: 0705

Mitochondrial Calcification-Induced Inflammation in Human Skeletal Muscle and Immune Cells
Abstract Number: 0973

Modeling of Clinical Phenotypes in SLE Based on Platelet Transcriptomic Analysis and FCGR2a Biallelic Variants
Abstract Number: 0840

Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
Abstract Number: 1432

Modulation of Auto-Inflammation with a Novel Selective Cyclic GMP-AMP Synthase (cGAS) Inhibitor in a Trex1-/- Model
Abstract Number: 0531

Molecular Heterogeneity Between Different Classes of Lupus Nephritis as Revealed by Kidney Biopsy Proteomics
Abstract Number: 1000

Molecular Mechanism of Inhibition of CD38 in Attenuation of Monosodium Urate Crystal-induced Inflammatory Responses in Macrophages
Abstract Number: 1501

Molecular Modelling Predicts Inhibition of Functional Effects of Anti-thrombin III on Factor Xa Mediated Complement Activation by Anti- Factor Xa IgG in SLE and APS

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].